TP53 and hematologic disorder: In the context of hematological malignancies, CGM097 has been evaluated in vitro, showing a potent and selective effect of inhibition of cell proliferation/viability of wild-type P53 primary AML cells and AML cell lines and in vivo antitumor effects in xenograft models, providing the rational for the testing of CGM097 in AML patients [112].